Increased bone resorption is central to the pathogenesis of osteoporosis. Several disorders of parathyroid function that occur with aging cause increased resorption and contribute to the bone loss seen in this disease. These include, an age-related rise in circulating levels of PTH, an increased prevalence of primary and secondary hyperparathyroidism and increased skeletal sensitivity to the resorbing actions of PTH following menopause. We have generated evidence that the interleukin6/interleukin-6 soluble receptor cytokine system (IL-6/IL-6sR) plays a critical role in PTH-mediated bone resorption. Circulating levels of IL-6 and IL-6sR are elevated in states of parathyroid hormone excess and correlate strongly with markers of bone resorption and rates of bone loss. PTH infusion in vivo causes serum levels of IL-6 and IL-6sR to rise and neutralizing IL-6 in vivo blocks PTH-induced bone resorption. Surprisingly, the liver contributes substantially to the PTH-induced increases in circulating IL-6/IL-6sR, with organ production rates sufficient to entirely explain the changes in circulating cytokine levels. To further explore these findings, we will: (1) define the role of hepatic IL-6 in PTH-induced bone resorption by generating mice with conditional knockout of IL-6 in hepatocytes and conditional knockout of the PTH receptor in hepatocytes. This will allow us to selectively eliminate the contribution of the liver to the changes induced by PTH in circulating IL-6/IL-6sR; (2) determine whether IL-6/IL-6sR acts co-operatively with RANKL, in either an additive or synergistic fashion to mediate PTH-induced bone resorption. The effects of IL-6/IL-6sR and RANKL separately and together on osteoclastogenesis and osteoclast activity will be determined in vitro. The effects of separate or combined infusions of IL-6/IL-6sR and RANKL in mice, at doses that match serum levels induced by PTH, will be used to determine in vivo additivity and to assess the contribution of circulating cytokines to the resorbing actions of PTH; (3) the role of the liver in PTH-induced increases in RANKL will be determined as well as the role of IL-6/IL-6sR in inducing soluble RANKL release in bone and liver. Finally, PTH infusions in women will allow us to determine whether the changes in serum RANKL levels seen in mice also occur in humans. These studies will better define the role of IL-6 in PTH-induced bone resorption, clarify its mechanisms of action and have important therapeutic implications.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG015345-07
Application #
6771802
Study Section
Orthopedics and Musculoskeletal Study Section (ORTH)
Program Officer
Carrington, Jill L
Project Start
1998-08-15
Project End
2007-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
7
Fiscal Year
2004
Total Cost
$367,875
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kerstetter, Jane E; Kenny, Anne M; Insogna, Karl L (2011) Dietary protein and skeletal health: a review of recent human research. Curr Opin Lipidol 22:16-20
Nakchbandi, Inaam A; Lang, Robert; Kinder, Barbara et al. (2008) The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab 93:967-73
Knopp, Eleanor; Troiano, Nancy; Bouxsein, Mary et al. (2005) The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone. Endocrinology 146:1983-90
Cruz, Dinna N; Brickel, Helen M; Wysolmerski, John J et al. (2002) Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant 2:62-7
Masiukiewicz, Urszula S; Mitnick, Maryann; Gulanski, Barbara I et al. (2002) Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women. J Clin Endocrinol Metab 87:2892-8
Nakchbandi, Inaam A; Mitnick, Mary Ann; Lang, Robert et al. (2002) Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87:4946-51
Boyden, Lynn M; Mao, Junhao; Belsky, Joseph et al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-21
Insogna, Karl; Mitnick, Maryann; Pascarella, Jennifer et al. (2002) Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. J Bone Miner Res 17 Suppl 2:N108-16
Cruz, D N; Wysolmerski, J J; Brickel, H M et al. (2001) Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation 72:83-8
Nakchbandi, I A; Mitnick, M A; Masiukiewicz, U S et al. (2001) IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 142:3850-6

Showing the most recent 10 out of 14 publications